Jan. 28 at 6:58 PM
$CRVO
There is no need to be afraid regarding dillution (enough towards Q3/2026), as a) There are still warants for 39 USD viable and b) Who says the offering will be a direct public offering?
If you read the date correctly, than this company is worth up to 1b. The medical potential for p38-MAPK is huge. There will also be a Phase 2 readout in mid 2026 for Motor Recovery After Acute Ischaemic Stroke. There is also currently not investigated potential to be used for depression. The company is today trading for around 50 Mio. USD., but the real value and growth goes behind billions in the next 5 years (any kind of dillution already considered).
On paper everything is right here, in the past it was hammered down when ever it squeezed a bit up and bleed out after it.
"Besides these, in general p38 mitogen-activated protein (p38-MAPK) signaling pathways inhibitory drugs like neflamapimod can have desirable effects on depression"
https://link.springer.com/chapter/10.1007/978-981-95-4522-3_12
